0001571049-17-004369.txt : 20170503 0001571049-17-004369.hdr.sgml : 20170503 20170503104646 ACCESSION NUMBER: 0001571049-17-004369 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170503 DATE AS OF CHANGE: 20170503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARQULE INC CENTRAL INDEX KEY: 0001019695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043221586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21429 FILM NUMBER: 17807744 BUSINESS ADDRESS: STREET 1: ONE WALL STREET CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 781-994-0300 MAIL ADDRESS: STREET 1: ONE WALL STREET CITY: BURLINGTON STATE: MA ZIP: 01803 10-Q 1 t1700267_10q.htm FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

For the Quarter Ended March 31, 2017

Commission File No. 000-21429

ArQule, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		04-3221586
(State of Incorporation)		(I.R.S. Employer Identification Number)

One Wall Street, Burlington, Massachusetts 01803

(Address of Principal Executive Offices)

(781) 994-0300

(Registrant’s Telephone Number, including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405) of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨		Accelerated filer x
Non-accelerated filer ¨		Smaller reporting company ¨
(Do not check if a smaller reporting company)		Emerging growth company ¨

Indicate If an emerging growth company, indicate by check by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x

Number of shares outstanding of the registrant’s Common Stock as of April 20, 2017:


Common Stock, par value $.01		71,146,597 shares outstanding

ARQULE, INC.

QUARTER ENDED MARCH 31, 2017

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. — Unaudited Condensed Financial Statements

	Condensed Balance Sheets (Unaudited) March 31, 2017 and December 31, 2016	3

	Condensed Statements of Operations and Comprehensive Loss (Unaudited) three months ended March 31, 2017 and 2016	4

	Condensed Statements of Cash Flows (Unaudited) three months ended March 31, 2017 and 2016	5

	Notes to Unaudited Condensed Financial Statements	6

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3. — Quantitative and Qualitative Disclosures about Market Risk		20

Item 4. — Controls and Procedures		20

PART II - OTHER INFORMATION		20

Item 1. — Legal Proceedings		20

Item 1A. — Risk Factors		20

Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds		20

Item 3. — Defaults Upon Senior Securities		20

Item 4. — Mine Safety Disclosures		20

Item 5. — Other Information		20

Item 6. — Exhibits		21

SIGNATURES		22

ARQULE, INC.

CONDENSED BALANCE SHEETS (Unaudited)

	March 31, 2017			December 31, 2016
	(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
ASSETS
Current assets:
Cash and cash equivalents	$	28,237		$	15,267
Marketable securities-short term		9,303			15,859
Prepaid expenses and other current assets		630			822
Total current assets		38,170			31,948

Property and equipment, net		156			180
Other assets		164			252
Total assets	$	38,490		$	32,380

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	7,164		$	8,700
Total current liabilities		7,164			8,700
Long-term liabilities:
Notes payable		14,337			—
Total liabilities		21,501			8,700

Commitment and contingencies

Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding		—			—
Common stock, $0.01 par value; 100,000,000 shares authorized; 71,146,597 and 71,146,209 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively		711			711
Additional paid-in capital		528,691			527,802
Accumulated other comprehensive income (loss)		(2	)		2
Accumulated deficit		(512,411	)		(504,835	)
Total stockholders’ equity		16,989			23,680
Total liabilities and stockholders’ equity	$	38,490		$	32,380

The accompanying notes are an integral part of these interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)

	THREE MONTHS ENDED MARCH 31,
	2017			2016
	(IN THOUSANDS, EXCEPT PER SHARE DATA)
Revenue:
Research and development revenue	$	—		$	1,227

Costs and expenses:
Research and development		5,194			4,198
General and administrative		2,074			2,044
Total costs and expenses		7,268			6,242

Loss from operations		(7,268	)		(5,015	)

Interest income		22			34
Interest expense		(330	)		—
Net loss		(7,576	)		(4,981	)

Unrealized gain (loss) on marketable securities		(4	)		29
Comprehensive loss	$	(7,580	)	$	(4,952	)

Basic and diluted net loss per share:
Net loss per share	$	(0.11	)	$	(0.08	)

Weighted average basic and diluted common shares outstanding		71,138			65,489

The accompanying notes are an integral part of these interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

	THREE MONTHS ENDED March 31,
	2017			2016
	(IN THOUSANDS)
Cash flows from operating activities:
Net loss	$	(7,576	)	$	(4,981	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		24			27
Amortization of premium (discount) on marketable securities		(3	)		26
Amortization of debt discount		60			—
Non-cash stock compensation		543			594
Changes in operating assets and liabilities:
Prepaid expenses and other assets		280			(115	)
Accounts payable and accrued expenses		(1,653	)		(843	)
Deferred revenue		—			(1,140	)
Net cash used in operating activities		(8,325	)		(6,432	)
Cash flows from investing activities:
Purchases of marketable securities		(1	)		(13,386	)
Proceeds from sale or maturity of marketable securities		6,556			10,498
Net cash provided by (used in) investing activities		6,555			(2,888	)
Cash flows from financing activities:
Proceeds from notes payable and warrants, net		14,740			—
Proceeds from stock offering, net		—			15,185
Proceeds from stock option exercises and employee stock plan purchases		—			114
Net cash provided by financing activities		14,740			15,299
Net increase in cash and cash equivalents		12,970			5,979
Cash and cash equivalents, beginning of period		15,267			13,983
Cash and cash equivalents, end of period	$	28,237		$	19,962

The accompanying notes are an integral part of these interim unaudited financial statements.

ARQULE, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine.

ArQule has a long history of kinase drug discovery and development, having discovered and introduced nine kinase inhibitors into clinical trials. Our drug discovery efforts have been informed by our historical expertise in chemistry, our work in rational drug design and by our insight into kinase binding and regulation. We have applied this knowledge to produce significant chemical matter for a number of kinase targets and to build an extensive library of proprietary compounds with the potential to target multiple kinases in oncology and other therapeutic areas, such as rare diseases. We expect to bring further preclinical programs forward and to interrogate our library against new targets beyond kinases either directly or with collaborators.

Our proprietary pipeline of product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. All of these programs are being developed in targeted, biomarker-defined patient populations. By seeking out subgroups of patients that are most likely to respond to our drugs, we intend to identify small, often orphan, indications that allow for focused and efficient development. At the same time, in addition to pursuing these potentially fast-to-market strategies, we also pursue development in other indications that could allow us to expand the utility of the drugs if approved. The pipeline includes the following wholly-owned compounds:

•

ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases, in Phase 2 for intrahepatic cholangiocarcinoma (iCCA) and in Phase 1b for multiple oncology indications;

•

ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in Phase 1 for multiple oncology indications and in the rare disease, Proteus syndrome, in partnership with the National Institutes of Health (NIH);

•

ARQ 751, a next-generation inhibitor of AKT, in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation;

•

ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, planned to advance to Phase 1 by Q3 2017; and

•

ARQ 761, a ß-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell death, in Phase 1/2 in multiple oncology indications in partnership with The University of Texas Southwest Medical Center.

Our most advanced partnered asset is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (“MET”) and its biological pathway. We licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”).

Our METIV-HCC trial was a pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single-agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Daiichi Sankyo and us. The primary endpoint was overall survival (OS) in the intent-to-treat (ITT) population, and the secondary endpoint was progression-free survival (PFS) in the same population. On February 17, 2017, we and Daiichi Sankyo announced that the METIV-HCC trial did not meet its primary endpoint of improving OS.

Our JET-HCC trial was a second pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single-agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Kyowa Hakko Kirin. The primary endpoint was PFS. On March 27, 2017, we reported that our partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan and that the trial did not meet its primary endpoint of improving PFS.

Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. In the three months ended March 31, 2017 and 2016, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $8.3 million and $6.4 million, respectively.

Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. On January 6, 2017, we entered into a loan and security agreement (the “Loan Agreement”) with a principal balance of $15 million (see Note 8). The terms of the Loan Agreement require payments of interest on a monthly basis through September 2018 and payments of interest and principal from October 2018 to August 2021. We anticipate that our cash, cash equivalents and marketable securities on hand at March 31, 2017, and the funds received on January 6, 2017 from our Loan Agreement will be sufficient to finance our operations for at least 12 months from the issuance date of these financial statements. We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

We have prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with our audited financial statements and footnotes related thereto for the year ended December 31, 2016 included in our annual report on Form 10-K filed with the SEC on March 9, 2017.

In our opinion, the accompanying unaudited condensed financial statements contain all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2017, and its results of operations and cash flows for the three months ended March 31, 2017 and March 31, 2016. The results of operations for such interim periods are not necessarily indicative of the results to be achieved for the full year. The condensed balance sheet at December 31, 2016, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements

2. COLLABORATIONS AND ALLIANCES

Daiichi Sankyo Tivantinib Agreement

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we shared development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. In each quarter the tivantinib collaboration costs we incurred were compared with those of Daiichi Sankyo. If our costs for the quarter exceeded Daiichi Sankyo’s, we recognized revenue on the amounts due to us under the contingency adjusted performance model. Revenue was calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter were less than those of Daiichi Sankyo, we reported the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeded the amount of milestones and royalties received, that excess was netted against milestones and royalties earned and was not reported as contra-revenue.

Our cumulative share of the Daiichi Sankyo Phase 3 costs through March 31, 2017 totaled $107.7 million. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through March 31, 2017 by $67.7 million which are not required to be repaid upon expiration of the agreement.

Revenue for this agreement was recognized using the contingency-adjusted performance model with an estimated development period through December 31, 2016. On February 17, 2017, we and Daiichi Sankyo announced that the METIV-HCC trial did not meet its primary end point of improving OS. As a result, we do not anticipate receiving further royalties or milestones in connection with the agreement.

For the quarters ended March 31, 2017 and 2016, zero and $0.7 million, respectively, were recognized as net revenue.

Kyowa Hakko Kirin Licensing Agreement

As previously reported, on April 27, 2007, we entered into an exclusive license agreement with Kyowa Hakko Kirin to develop and commercialize tivantinib in Japan and parts of Asia. Revenue for this agreement was recognized using the contingency-adjusted performance model with an estimated development period through December 31, 2016. On March 27, 2017, we reported that our partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of improving PFS. As a result, we do not anticipate receiving further royalties or milestones in connection with the agreement.

For the quarters ended March 31, 2017 and 2016, zero and $0.5 million, respectively, were recognized as revenue.

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.

We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.

We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).

For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.

Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The following is a summary of the fair value of available-for-sale marketable securities we held at March 31, 2017 and

December 31, 2016:

March 31, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	9,305	$	—	$	(2	)	$	9,303
Total available-for-sale marketable securities	$	9,305	$	—	$	(2	)	$	9,303

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	15,857	$	7	$	(5	)	$	15,859
Total available-for-sale marketable securities	$	15,857	$	7	$	(5	)	$	15,859

Our available-for-sale marketable securities in a loss position at March 31, 2017, and December 31, 2016 were in a continuous unrealized loss position for less than 12 months.

The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:

	March 31, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	2,947	$	2,947	$	—	$	—
Corporate debt securities-short term		9,303		—		9,303		—
Total	$	12,250	$	2,947	$	9,303	$	—

	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	12,923	$	12,923	$	—	$	—
Corporate debt securities-short term		15,859		—		15,859		—
Total	$	28,782	$	12,923	$	15,859	$	—

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at March 31, 2017 and December 31, 2016:

	March 31, 2017		December 31, 2016
Accounts payable	$	610	$	710
Accrued payroll		772		1,856
Accrued outsourced pre-clinical and clinical fees		4,682		5,461
Accrued professional fees		663		363
Other accrued expenses		437		310
	$	7,164	$	8,700

5. NET LOSS PER SHARE

Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three months ended March 31, 2017, include 9,504,090 shares that would be issued upon the exercise of outstanding employee stock options and 354,330 shares that would be issued upon the exercise of the warrants issued in conjunction with our January 6, 2017 loan agreement. Potential common shares, for the three months ended March 31, 2016, include 9,477,198 shares that would be issued upon the exercise of outstanding employee stock options, and 3,567,956 shares that would have been issued upon exercise of stock options issued in our February 26, 2016 stock offering.

6. STOCK-BASED COMPENSATION AND STOCK PLANS

Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the three months ended March 31, 2017 and 2016.

The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:

	Three Months Ended March 31,
	2017		2016
Research and development	$	130	$	190
General and administrative		413		404
Total stock-based compensation expense	$	543	$	594

In the three months ended March 31, 2017 and 2016, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.

Option activity under our stock plans for the three months ended March 31, 2017 was as follows:

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016		8,715,048		$	3.71
Granted		982,500			1.53
Exercised		—			—
Cancelled		(193,458	)		5.98
Outstanding as of March 31, 2017		9,504,090		$	3.44

Exercisable as of March 31, 2017		6,481,588		$	4.28

The aggregate intrinsic value of options outstanding at March 31, 2017 was zero related to exercisable options. The weighted average fair value of options granted in the three months ended March 31, 2017 and 2016 was $0.93 and $1.12 per share, respectively. The intrinsic value of options exercised in the three months ended March 31, 2017 was zero.

Shares vested, expected to vest and exercisable at March 31, 2017 are as follows:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at March 31, 2017		9,326,234	$	3.44		5.9	$	—
Exercisable at March 31, 2017		6,481,588	$	4.28		4.5	$	—

The total compensation cost not yet recognized as of March 31, 2017 related to non-vested option awards was $3.0 million, which will be recognized over a weighted-average period of 3.1 years. During the three months ended March 31, 2017, 182,877 shares expired and 10,581 shares were forfeited. The weighted average remaining contractual life for options exercisable at March 31, 2017 was 4.5 years.

In 2013, we granted 242,697 shares of restricted stock to employees, vesting annually over a four year period. The weighted average fair value of the restricted stock at the time of grant in 2013 was $2.51 per share, and is being expensed ratably over the vesting period. Through March 31, 2017, 82,617 shares have been forfeited, and 160,080 shares have vested. We recognized share-based compensation expense related to restricted stock of $8 and $22 for the three months ended March 31, 2017 and 2016, respectively.

Restricted stock activity under the Plan for the three months ended March 31, 2017 was as follows:

Restricted Stock	Number of Shares			Weighted Average Grant Date Fair Value
Unvested as of December 31, 2016		29,276		$	2.51
Vested		(29,276	)		2.51
Unvested as of March 31, 2017		—		$	—

The fair value of restricted stock that vested in the three months ended March 31, 2017 and 2016 was $46 and $47, respectively.

7. STOCK OFFERING

On February 26, 2016, we entered into definitive stock purchase agreements with certain institutional and accredited investors. In conjunction with this stock offering we issued 8,027,900 shares of our common stock and non-transferable options for 3,567,956 shares of our common stock for aggregate net proceeds of $15.2 million. Each option was exercisable for $2.50 per share and they all expired on March 22, 2017.

8. LOAN AGREEMENT

On January 6, 2017, Oxford Finance LLC, as collateral agent and a lender (the “Lender”), and any additional lenders that may become parties thereto, entered into a loan and security agreement with us (the “Loan Agreement”).

Pursuant to the terms of the Loan Agreement, the Lender issued us a loan in the principal amount of $15.0 million. The loan will bear interest at the rate equal to (a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. The applicable interest rate on the loan at March 31, 2017 was 7.83%. We will have interest-only payments for 18 months, followed by an amortization period of 36 months. The maturity date of the loan is July 1, 2021.

The expected remaining repayment of the $15 million loan principal is as follows:

2018	$	1,667
2019		5,000
2020		5,000
2021		3,333
	$	15,000

Upon the earlier of prepayment or the maturity date, we will pay to the Lender a final payment of 6% of the full principal amount of the loan. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.

We paid the Lender an upfront facility fee of $75,000.

Pursuant to the terms of the Loan Agreement, we are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent, including, without limitation, incurring certain additional indebtedness, entering into certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. We are in compliance with the loan covenants at March 31, 2017.

Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by us thereunder will begin to bear interest at a rate that is 5% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lender. Events of default under the Loan Agreement include, among other things, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in our business, operations or financial condition ; the rendering of certain types of fines or judgments against us; any breach by us of any covenant (subject to cure for certain covenants only) made in the Loan Agreement; and the failure of any representation or warranty made by us in connection with the Loan Agreement to be correct in all material respects when made.

We have granted Lender, a security interest in substantially all of our personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to the Lender under the Loan Agreement. We have also agreed not to encumber any of our intellectual property without required lenders’ prior written consent.

In connection with entering into the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of 354,330 shares of our common stock (the “Lender Warrants”). The warrants are exercisable immediately, have a per-share exercise price of $1.27 and have a term of ten years. We have recorded the relative fair value of the warrants as a discount to the carrying value of the notes payable with a corresponding increase to additional paid in capital.

9. RECENT ACCOUNTING PRONOUNCEMENTS

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted this ASU in 2017 and it will not have a material impact on our financial position, results of operations or statement of cash flows.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.

In August 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods ending after December 15, 2016, and for annual and interim periods thereafter and we adopted this ASU in 2016.

During the quarter ended June 30, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We evaluated this ASU and determined that it will not have a material impact on our financial position or results of operations.

10. INCOME TAXES

As of December 31, 2016, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $382,781, $202,137 and $27,779 respectively, which expire at various dates through 2036. Approximately $15,080 of our federal NOL and $929 of our state NOL were generated from excess tax deductions from share-based awards.

The Company adopted ASU No. 2016-09 in the first quarter of 2017. The recognition of the excess tax benefits from share-base payments mentioned above increased deferred tax assets and retained earnings accordingly. As the company doesn’t expect taxable income in the foreseeable future, we reserved the full amount at the time of the recognition and there was no impact on the net positions of deferred tax assets and retained earnings. The amount of excess tax benefits or deficiencies will fluctuate from period to period based on the price of our stock, the volume of share-based instruments settled or vested, and the value assigned to employee equity awards under U.S. GAAP and these fluctuations did not affect our net deferred tax position in the first quarter of 2017.

At March 31, 2017 and December 31, 2016, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of March 31, 2017 and December 31, 2016, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2013 through 2016 and our state tax returns for the tax years 2013 through 2016 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards.

Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2017, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our condensed financial statements and accompanying notes contained in this quarterly report on Form 10-Q and our audited financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016.

•

ARQ 751, a next-generation inhibitor of AKT, in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation;

•

ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, planned to advance to Phase 1 by Q3 2017; and

•

Our most advanced partnered asset was tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (“MET”) and its biological pathway. We licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”).

Our METIV-HCC trial was a pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Daiichi Sankyo and us. The primary endpoint was overall survival (OS) in the intent-to-treat (ITT) population, and the secondary endpoint was progression-free survival (PFS) in the same population. On February 17, 2017, we and Daiichi Sankyo announced that the METIV-HCC trial did not meet its primary endpoint of improving.

Our JET-HCC was a pivotal Phase 3, randomized, double-blind, controlled study of tivantinib as single-agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Kyowa Hakko Kirin in Japan. On March 27, 2017, we reported that our partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of improving PFS.

We have incurred a cumulative deficit of approximately $512 million from inception through March 31, 2017. We recorded a net loss for 2015 and 2016 and expect a net loss for 2017.

As previously reported, on December 18, 2008, we entered into a license, co-development and co-commercialization agreement with Daiichi Sankyo to conduct research, clinical trials and the commercialization of tivantinib in human cancer indications in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin has exclusive rights for development and commercialization. On February 17, 2017, we and Daiichi Sankyo announced that the MET-IV-HCC trial did not meet its primary end point of improving OS. As a result, we do not anticipate receiving further royalties or milestones in connection with the agreement.

LIQUIDITY AND CAPITAL RESOURCES

	March 31,		December 31,		Increase (decrease)
	2017		2016		$		%
	(in millions)
Cash, cash equivalents and marketable securities-short term	$	37.5	$	31.1		6.4		21	%
Working capital		31.0		23.2		7.8		33	%

	Q1 2017			Q1 2016			Increase (decrease)
	(in millions)
Cash flow from:
Operating activities	$	(8.3	)	$	(6.4	)	$	(1.9	)
Investing activities		6.6			(2.9	)		9.5
Financing activities		14.7			15.3			(0.6	)

Cash flow from operating activities. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. For the quarters ended March 31, 2017 and 2016, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $8.3 million and $6.4 million, respectively.

Cash flow from investing activities. Our net cash provided by investing activities of $6.6 million for the quarter ended March 31, 2017, was comprised of net maturities of of marketable securities. Our net cash provided by investing activities of $2.9 million for the quarter ended March 31, 2016 was comprised primarily of net maturities of marketable securities of $13.4 million and net purchases of marketable securities of $10.5 million. The composition and mix of cash, cash equivalents and marketable securities may change frequently as a result of our constant evaluation of conditions in financial markets, the maturity of specific investments, and our near term liquidity needs.

Cash flow from financing activities. Our net cash provided by financing activities of $14.7 million for the quarter ended March 31, 2017, was comprised of $14.7 million net proceeds from the loan and security agreement that we entered into on January 6, 2017. Our net cash provided by financing activities of $15.3 million for the quarter ended March 31, 2016, was comprised of net proceeds from our February 26, 2016 stock offering of $15.2 million and $0.1 million from stock option exercises and employee stock plan purchases.

Our cash equivalents and marketable securities typically include U.S. Treasury bill funds, money market funds, commercial paper, and U.S. federal and state agency backed certificates that have investment grade ratings. Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

On February 26, 2016 we entered into definitive stock purchase agreements with certain institutional and accredited investors. In conjunction with this stock offering we issued 8,027,900 shares of our common stock and non-transferable options for 3,567,956 shares of our common stock for aggregate net proceeds of $15.2 million. Each option was exercisable for $2.50 per share and they all expired on March 22, 2017.

On January 6, 2017, we entered into a loan and security agreement in the principal amount of $15.0 million. The loan will bear interest at a minimum of 7.6% per annum and the interest rate will float based upon the 30 day U.S. LIBOR rate. We will have interest-only payments for 18 months, followed by an amortization period of 36 months. The maturity date of the loan is July 1, 2021.

We anticipate that our cash, cash equivalents and marketable securities on hand at March 31, 2017 and the funds received on January 6, 2017 from our loan and security agreement mentioned above will be sufficient to finance our operations into at least mid-2018.

Our contractual obligations were comprised of the following as of March 31, 2017 (in thousands):

	Payment due by period
Contractual Obligations	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
Notes payable	$	15,900	$	—	$	8,333	$	7,567	$	—
Operating lease obligations		1,670		549		1,121		—		—
Purchase obligations		4,682		4,682		—		—		—
Total	$	22,252	$	5,231	$	9,454	$	7,567	$	—

In January 2015, we entered into a lease agreement for a new headquarters facility. The lease commenced on May 1, 2015 for a term of five years and three months with an average annual rental rate of $455 thousand. The obligations for this new facility are included in the table above.

Purchase obligations are comprised primarily of outsourced preclinical and clinical trial expenses and payments to license certain intellectual property to support our research efforts.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For additional information, please see the discussion of our significant accounting policies in Note 2 to the Financial Statements included in our Annual Report for the fiscal year ended December 31, 2016 on Form 10-K filed with the SEC on March 9, 2017.

RESULTS OF OPERATIONS

The following are the results of operations for the three months ended March 31, 2017 and 2016:

Revenue

					Increase (decrease)
	2017		2016		$			%
	(in millions)
For the three months ended March 31:
Research and development revenue	$	—	$	1.2	$	(1.2	)		(100	)%

Research and development revenue in the three months ended March 31, 2017 was zero due to the end of the estimated development period on December 31, 2016 for both the Daiichi Sankyo tivantinib development agreement and the Kyowa Hakko Kirin exclusive license agreement. Research and development revenue in the three months ended March 31, 2016 revenue is comprised of revenue of $0.5 million from our Daiichi Sankyo METIV-HCC trial and $0.7 million from our Kyowa Hakko Kirin JET-HCC trial.

Research and development

					Increase (decrease)
	2017		2016		$		%
	(in millions)
For the three months ended March 31:
Research and development	$	5.2	$	4.2	$	1.0		24	%

Research and development expense in the quarter ended March 31, 2017 increased by $1.0 million primarily due to higher outsourced preclinical, clinical and product development costs. At March 31, 2017 we had 20 employees dedicated to our research and development program compared to 21 at March 31, 2016.

Overview

Our research and development expense consists primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to research organizations in conjunction with pre-clinical animal studies, costs of materials used in research and development, consulting, license, and sponsored research fees paid to third parties and depreciation of associated laboratory equipment. We expect that our research and development expense will remain significant as we continue to develop our portfolio of oncology programs.

We have not accumulated and tracked our internal historical research and development costs or our personnel and personnel-related costs on a program-by-program basis. Our employee and infrastructure resources are allocated across several projects, and many of our costs are directed to broadly applicable research endeavors. As a result, we cannot state the costs incurred for each of our oncology programs on a program-by-program basis.

The expenses incurred by us to third parties for pre-clinical and clinical trials in the current quarter and since inception of our lead clinical stage program were as follows (in millions):

Oncology program	Current status	Three Months Ended March 31, 2017		Program-to- date
Met program—Tivantinib	Phase 3	$	0.1	$	84.9

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we shared development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through March 31, 2017 by $67.7 million and is not reflected in the above table.

Our future research and development expenses in support of our current and future oncology programs will be subject to numerous uncertainties in timing and cost to completion. We test potential products in numerous pre-clinical studies for safety, toxicology, and efficacy. We may conduct multiple clinical trials for each product. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials may take several years or more, and the length of time generally varies substantially according to the type, complexity, novelty, and intended use of a product. It is not unusual for the pre-clinical and clinical development of each of these types of products to take nine years or more, and for total development costs to exceed $500 million for each product.

We estimate that clinical trials of the type generally needed to secure new drug approval are typically completed over the following timelines:

		Estimated Completion
Clinical Phase		Period
Phase 1		1 – 2 years
Phase 2		2 – 3 years
Phase 3		2 – 4 years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others, the following:

●

the number of clinical sites included in the trials;

●

the length of time required to enroll suitable patients;

●

the number of patients that ultimately participate in the trials;

●

the duration of patient follow-up to ensure the absence of long-term product-related adverse events; and

●

the efficacy and safety profile of the product.

An element of our business strategy is to pursue the research and development of a broad pipeline of products. This is intended to allow us to diversify the risks associated with our research and development expenditures. As a result, we believe our future capital requirements and future financial success do not substantially depend on any one product. To the extent we are unable to build and maintain a broad pipeline of products, our dependence on the success of one or a few products increases.

Our strategy includes entering into alliance arrangements with third parties to participate in the development and commercialization of our products, such as our collaboration agreements with Daiichi Sankyo and Kyowa Hakko Kirin. In the event that third parties have control over the clinical trial process for a product, the estimated completion date would be under control of that third party rather than under our control. We cannot forecast with any degree of certainty whether our products will be subject to future collaborative arrangements or how such arrangements would affect our development plans or capital requirements.

As a result of the uncertainties discussed above, we make significant estimates in determining the duration and completion costs of our oncology programs or when and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our oncology programs in a timely manner or our failure to enter into appropriate collaborative agreements could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time-to-time in order to continue with our product development strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

General and administrative

					Increase (decrease)
	2017		2016		$		%
	(in millions)
For the three months ended March 31:
General and administrative	$	2.1	$	2.0	$	0.1		1	%

General and administrative expense increased in the first quarter of 2017 principally due to higher labor related costs. General and administrative headcount was 14 at March 31, 2017, compared to 16 at March 31, 2016.

Interest income and interest expense

					Increase (decrease)
	2017		2016		$			%
	(in thousands)
For the three months ended March 31:
Interest income	$	22	$	34	$	(12	)		(35	)%
Interest expense		330		—		330			100	%

Interest income is derived from our portfolio of cash, cash equivalents and investments and decreased in the first quarter of 2017 primarily due to a decrease in our portfolio balance. Interest expense is from the loan agreement we entered into on January 6, 2017.

RECENT ACCOUNTING PRONOUNCEMENTS

For a discussion of new accounting pronouncements please read Note 9, Recent Accounting Pronouncements to our financial statements included in this report.

FORWARD LOOKING STATEMENTS

In addition to historical information, this report contains forward-looking statements. You can identify these forward-looking statements by their use of words such as “anticipate,” “assume,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will” and other words and terms of similar meaning. You also can identify them by the fact that they do not relate strictly to historical or current facts. All statements which address operating performance, events or developments that the Company expects or anticipates will occur in the future, such as projections about its future results of operations, its financial condition, research, development and commercialization of its products and anticipated trends in its business are forward-looking statements.

In this report we make forward-looking statements regarding our drug development pipeline and our existing and planned clinical trials as well as projected financial results and our ability to fund operations with current cash, cash equivalents and marketable securities.

Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. For example, pre-clinical efforts associated with our product pipeline may fail or prove disappointing because our technology platform did not produce candidates with the desired characteristics. Animal xenograft pre-clinical studies may be unpredictive of human response. Positive information about early stage clinical trial results will not ensure that later stage or larger scale clinical trials will be successful.

Furthermore, our drugs may not demonstrate promising therapeutic effects; in addition, they may not demonstrate appropriate safety profiles in ongoing or later stage or larger scale clinical trials as a result of known or as yet unidentified side effects. The results achieved in later stage trials may not be sufficient to meet applicable regulatory standards. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing our drugs that could lead us or our partner to discontinue development.

Even if later stage clinical trials are successful, the risk exists that unexpected concerns may arise from analysis of data or from additional data or that obstacles may arise or issues be identified in connection with review of clinical data with regulatory authorities or that regulatory authorities may disagree with our view of the data or require additional data or information or additional studies. Also, the planned timing of initiation of clinical trials and the duration and conclusion of such trials for our drugs are subject to the ability of the company to enroll patients, enter into agreements with clinical trial sites and investigators, and other technical hurdles and issues that may not be resolved.

We also make forward-looking statements regarding the adequacy of our financial resources. Our capital resources may not be adequate because our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, the outcomes of our clinical trials, our ability to enter into additional corporate collaborations in the future and the terms of such collaborations, results of research and development, the need for currently unanticipated capital expenditures, competitive and technological advances, acquisitions, financial market conditions and other factors. Additionally, our corporate collaborators may terminate their agreements with us, thereby eliminating that source of funding, because we may fail to satisfy the prescribed terms of the collaborations or for other reasons.

We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product generating revenues. If we experience increased losses, we may have to seek additional financing from public and private sales of our securities, including equity securities. There can be no assurance that additional funding will be available when needed or on acceptable terms.

The factors, risks and uncertainties referred to above and others are more fully described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on February 28, 2017, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The forward-looking statements contained herein represent our judgment as of the date of this report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We own financial instruments that are sensitive to market risk as part of our investment portfolio. We have implemented policies regarding the amount and credit ratings of investments. Our investment portfolio is used to preserve our capital until it is used to fund operations, including our research and development activities. Our investments are evaluated quarterly to determine the fair value of the portfolio.

Our cash equivalents and marketable securities typically include commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings.

Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1%, this would not result in a material change in the fair value of our investment portfolio.

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2017. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2017, our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

There have been no changes in our internal control over financial reporting during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. — LEGAL PROCEEDINGS. None.

ITEM 1A. — RISK FACTORS. For information regarding factors that could affect our results of operations, financial condition and liquidity, see the risk factors discussion provided under “Risk Factors” in Item 1A of ArQule’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 10, 2017, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See also, “Forward-Looking Statements” included in this Quarterly Report on Form 10-Q.

ITEM 2. — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None.

ITEM 3. — DEFAULTS UPON SENIOR SECURITIES. None.

ITEM 4. — MINE SAFETY DISCLOSURES. Not applicable.

ITEM 5. — OTHERS INFORMATION. None.

ITEM 6. — EXHIBITS.

EXHIBIT NO.		DESCRIPTION

10.1		Form of Performance-based Option Agreement.* Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on April 10, 2017 (File No. 000-21429) and incorporated herein by reference.
10.2		Fourth Amendment to Employment Agreement with Paolo Pucci.* Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on April 10, 2017 (File No. 000-21429) and incorporated herein by reference.
10.3		Fifth Amendment to Employment Agreement with Peter Lawrence.* Filed as Exhibit 10.3 to our Current Report on Form 8-K filed on April 10, 2017 (File No. 000-21429) and incorporated herein by reference.
10.4		Fourth Amendment to Employment Agreement with Brian Schwartz.* Filed as Exhibit 10.4 to our Current Report on Form 8-K filed on April 10, 2017 (File No. 000-21429) and incorporated herein by reference.
31.1		Rule 13a-14(a) Certificate of Chief Executive Officer, filed herewith.
31.2		Rule 13a-14(a) Certificate of Principal Financial Officer, filed herewith.
32		Rule 13a-14(b) Certificate of Chief Executive Officer and Chief Financial Officer, filed herewith.
101		Interactive Data File

		*Management compensatory plan or agreement

ARQULE, INC.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ArQule, Inc.

Date: May 3, 2017	/s/ PETER S. LAWRENCE
	Peter S. Lawrence
	President and Chief Operating Officer
	(Principal Financial Officer)

	/s/ ROBERT J. WEISKOPF
	Robert J. Weiskopf
	Chief Financial Officer and Treasurer
	(Principal Accounting Officer)

EX-31.1 2 t1700267_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER

I, Paolo Pucci, certify that:

I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 3, 2017

		/s/ PAOLO PUCCI
		Paolo Pucci
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 t1700267_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATE OF THE PRINCIPAL FINANCIAL OFFICER

I, Peter S. Lawrence, certify that:

I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 3, 2017

		/s/ PETER S. LAWRENCE
		Peter S. Lawrence
		President and Chief Operating Officer
		(Principal Financial Officer)

EX-32 4 t1700267_ex32.htm EXHIBIT 32

Exhibit 32

ARQULE, INC.

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

The undersigned, Paolo Pucci Chief Executive Officer (Principal Executive Officer) of ArQule, Inc. (the “Company”) and Peter S. Lawrence, President and Chief Operating Officer (Principal Financial Officer), of the Company, both duly elected and currently serving, hereby certify that, to the best of his or her knowledge:

the quarterly report on Form 10-Q for the period ending March 31, 2017, filed on behalf of the Company pursuant to the Securities Exchange Act of 1934 (the “Exchange Act”) and containing the financial statements of the Company, fully complies with the requirements of section 13(a) of the Exchange Act; and

the information contained in such quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by such quarterly report.

This certification accompanies the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2017, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the “2002 Act”) and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act.

This certification is being made for the exclusive purpose of compliance by the Principal Executive Officer and Principal Financial Officer of the Company with the requirements of Section 906 of the 2002 Act, and may not be disclosed, distributed or used by any person for any reason other than as specifically required by law.

IN WITNESS WHEREOF, the undersigned have executed this Certificate as of the 3rd day of May 2017.

/s/ PAOLO PUCCI
Name:	Paolo Pucci
Title:	Chief Executive Officer
	(Principal Executive Officer)

/s/ PETER S. LAWRENCE
Name:	Peter S. Lawrence
Title:	President and Chief Operating Officer
	(Principal Financial Officer)

EX-101.INS 5 arql-20170331.xml XBRL INSTANCE DOCUMENT 0001019695 us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001019695 2015-12-31 0001019695 arql:DefinitiveStockPurchaseAgreementsMember 2016-02-01 2016-02-26 0001019695 2016-01-01 2016-03-31 0001019695 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2016-01-01 2016-03-31 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001019695 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001019695 arql:DaiichiSankyoTivantinibAgreementMember arql:Phase3CollaborationCostsMember 2016-01-01 2016-03-31 0001019695 2016-03-31 0001019695 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2016-01-01 2016-12-31 0001019695 2016-12-31 0001019695 us-gaap:RestrictedStockMember 2016-12-31 0001019695 us-gaap:EmployeeStockOptionMember 2016-12-31 0001019695 us-gaap:DomesticCountryMember 2016-12-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:CurrentMember 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 us-gaap:ResearchMember 2016-12-31 0001019695 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 2017-01-06 0001019695 2017-01-01 2017-01-06 0001019695 2017-01-01 2017-03-31 0001019695 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2017-01-01 2017-03-31 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001019695 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0001019695 arql:DaiichiSankyoTivantinibAgreementMember arql:Phase3CollaborationCostsMember 2017-01-01 2017-03-31 0001019695 2017-03-31 0001019695 us-gaap:RestrictedStockMember 2017-03-31 0001019695 us-gaap:EmployeeStockOptionMember 2017-03-31 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:CurrentMember 2017-03-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2017-03-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2017-03-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-03-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001019695 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0001019695 2017-04-20 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure ARQULE INC 0001019695 arql --12-31 Accelerated Filer 71146597 10-Q 2017-03-31 false 2017 Q1

13983000

19962000

15267000

28237000

15859000

9303000

822000

630000

31948000

38170000

180000

156000

252000

164000

32380000

38490000

8700000

7164000

8700000

7164000

14337000

8700000

21501000

711000

527802000

528691000

2000

-2000

-504835000

-512411000

23680000

16989000

32380000

38490000

0.01

1000000

0.01

100000000

71146209

71146597

71146209

71146597

1227000 500000 700000 0 0

4198000

5194000

2044000

2074000

6242000

7268000

-5015000

-7268000

34000

22000

330000

-4981000

-7576000

29000

-4000

-4952000

-7580000

-0.08

-0.11

65489

71138

27000

24000

-26000

3000

60000

594000

543000

115000

-280000

-843000

-1653000

-1140000

-6432000

-8325000

13386000

1000

10498000

6556000

-2888000

6555000

14740000

15185000

114000

15299000

14740000

5979000

12970000

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of the fair value of available-for-sale marketable securities we held at March 31, 2017 and</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">December 31, 2016:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">March 31, 2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-style: italic;">Security type</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 580.13px; text-align: left; text-indent: -8.65pt; padding-bottom: 2px; padding-left: 17.3pt;">Corporate debt securities-short term</td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 15.2px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180.8px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">9,305</td><td style="width: 15.2px; text-align: left; padding-bottom: 2px;"> </td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 15.2px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180.8px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">—</td><td style="width: 15.2px; text-align: left; padding-bottom: 2px;"> </td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 15.2px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180.8px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(2</td><td style="width: 15.2px; text-align: left; padding-bottom: 2px;">)</td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 14.4px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">9,303</td><td style="width: 14.4px; text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,305</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">(2</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,303</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">December 31, 2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="font-style: italic;" nowrap="nowrap">Security type</td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 580.13px; text-align: left; text-indent: -8.65pt; padding-bottom: 2px; padding-left: 17.3pt;">Corporate debt securities-short term</td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 15.2px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180.8px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">15,857</td><td style="width: 15.2px; text-align: left; padding-bottom: 2px;"> </td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 15.2px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180.8px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">7</td><td style="width: 15.2px; text-align: left; padding-bottom: 2px;"> </td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 15.2px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180.8px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(5</td><td style="width: 15.2px; text-align: left; padding-bottom: 2px;">)</td><td style="width: 15.2px; padding-bottom: 2px;"> </td><td style="width: 14.4px; text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td><td style="width: 180px; text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">15,859</td><td style="width: 14.4px; text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">15,857</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">7</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">(5</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Our available-for-sale marketable securities in a loss position at March 31, 2017, and December 31, 2016 were in a continuous unrealized loss position for less than 12 months.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><b>March 31,</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><b>2017</b></p></td><td style="padding-bottom: 2px;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 603.2px; text-align: left;">Cash equivalents</td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">2,947</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">2,947</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">—</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 14.4px; text-align: left;">$</td><td style="width: 180px; text-align: right;">—</td><td style="width: 14.4px; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">9,303</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">9,303</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -8.65pt; padding-bottom: 4px; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">12,250</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,947</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,303</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 603.2px; text-align: left;">Cash equivalents</td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">12,923</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">12,923</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">—</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 14.4px; text-align: left;">$</td><td style="width: 180px; text-align: right;">—</td><td style="width: 14.4px; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -8.65pt; padding-bottom: 4px; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">28,782</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">12,923</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table>

<div><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> Accounts payable and accrued expenses include the following at March 31, 2017 and December 31, 2016:</p><p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 878px;">Accounts payable</td><td style="width: 13px;"> </td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 151px;">610</td><td style="text-align: left; width: 12px;"> </td><td style="width: 12px;"> </td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 150px;">710</td><td style="text-align: left; width: 12px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued payroll</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">772</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">1,856</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued outsourced pre-clinical and clinical fees</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">4,682</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">5,461</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued professional fees</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">663</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">363</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Other accrued expenses</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">437</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">310</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">7,164</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">8,700</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table></div>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>6. STOCK-BASED COMPENSATION AND STOCK PLANS</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the three months ended March 31, 2017 and 2016.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6" nowrap="nowrap">Three Months Ended<br />March 31,</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 832.47px; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt;">Research and development</td><td style="width: 12.8px;"> </td><td style="width: 12px; text-align: left;">$</td><td style="width: 144px; text-align: right;">130</td><td style="width: 12px; text-align: left;"> </td><td style="width: 12px;"> </td><td style="width: 12px; text-align: left;">$</td><td style="width: 144px; text-align: right;">190</td><td style="width: 12px; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -8.65pt; padding-bottom: 2px; padding-left: 8.65pt;">General and administrative</td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">413</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">404</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -8.65pt; padding-bottom: 4px; padding-left: 17.3pt;">Total stock-based compensation expense</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">543</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">594</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the three months ended March 31, 2017 and 2016, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Option activity under our stock plans for the three months ended March 31, 2017 was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><b>Stock Options</b></td><td style="text-align: center;" nowrap="nowrap"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><b>Number of</b><br /><b>Shares</b></td><td style="text-align: center;" nowrap="nowrap"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><b>Weighted</b><br /><b>Average</b><br /><b>Exercise Price</b></td><td style="text-align: center;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="width: 923.67px; text-indent: -8.65pt; padding-left: 8.65pt;">Outstanding as of December 31, 2016</td><td style="width: 27.2px;"> </td><td style="width: 13.6px;" nowrap="nowrap"> </td><td style="width: 163.2px; text-align: right;">8,715,048</td><td style="width: 27.2px;"> </td><td style="width: 13.6px;">$</td><td style="width: 162.4px; text-align: right;">3.71</td><td style="width: 12.8px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Granted</td><td> </td><td> </td><td style="text-align: right;">982,500</td><td> </td><td> </td><td style="text-align: right;">1.53</td><td> </td></tr><tr><td style="text-indent: -8.65pt; padding-left: 8.65pt; vertical-align: bottom;">Exercised</td><td style="vertical-align: bottom;"> </td><td style="vertical-align: bottom;"> </td><td style="text-align: right; vertical-align: top;">—</td><td style="vertical-align: top;"> </td><td style="vertical-align: bottom;"> </td><td style="text-align: right; vertical-align: bottom;">—</td><td style="vertical-align: bottom;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Cancelled</td><td> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(193,458</td><td>)</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">5.98</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Outstanding as of March 31, 2017</td><td> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,504,090</td><td> </td><td style="text-align: left; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">3.44</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;"> </td><td> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable as of March 31, 2017</td><td> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">6,481,588</td><td> </td><td style="text-align: left; vertical-align: bottom; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">4.28</td><td> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The aggregate intrinsic value of options outstanding at March 31, 2017 was zero related to exercisable options. The weighted average fair value of options granted in the three months ended March 31, 2017 and 2016 was $0.93 and $1.12 per share, respectively. The intrinsic value of options exercised in the three months ended March 31, 2017 was zero.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Shares vested, expected to vest and exercisable at March 31, 2017 are as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Shares</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted-<br />Average<br />Exercise Price</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in years)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 591.67px; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt;">Vested and unvested expected to vest at March 31, 2017</td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 180.8px; text-align: right;">9,326,234</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;">$</td><td style="width: 180.8px; text-align: right;">3.44</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 180.8px; text-align: right;">5.9</td><td style="width: 15.2px; text-align: left;"> </td><td style="width: 15.2px;"> </td><td style="width: 14.4px; text-align: left;">$</td><td style="width: 180px; text-align: right;">—</td><td style="width: 14.4px; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable at March 31, 2017</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">6,481,588</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">4.28</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">4.5</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">—</td><td style="text-align: left;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The total compensation cost not yet recognized as of March 31, 2017 related to non-vested option awards was $3.0 million, which will be recognized over a weighted-average period of 3.1 years. During the three months ended March 31, 2017, 182,877 shares expired and 10,581 shares were forfeited. The weighted average remaining contractual life for options exercisable at March 31, 2017 was 4.5 years.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In 2013, we granted 242,697 shares of restricted stock to employees, vesting annually over a four year period. The weighted average fair value of the restricted stock at the time of grant in 2013 was $2.51 per share, and is being expensed ratably over the vesting period. Through March 31, 2017, 82,617 shares have been forfeited, and 160,080 shares have vested. We recognized share-based compensation expense related to restricted stock of $8 and $22 for the three months ended March 31, 2017 and 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Restricted stock activity under the Plan for the three months ended March 31, 2017 was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">Restricted Stock</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Number of Shares</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted Average<br />Grant Date<br />Fair Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 844px;">Unvested as of December 31, 2016</td><td style="width: 12.8px;"> </td><td style="width: 12px; text-align: left;"> </td><td style="width: 144px; text-align: right;">29,276</td><td style="width: 12px; text-align: left;"> </td><td style="width: 12px;"> </td><td style="width: 12px; text-align: left;">$</td><td style="width: 144px; text-align: right;">2.51</td><td style="width: 12px; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -8.65pt; padding-bottom: 2px; padding-left: 17.3pt;">Vested</td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(29,276</td><td style="text-align: left; padding-bottom: 2px;">)</td><td style="padding-bottom: 2px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">2.51</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4px;">Unvested as of March 31, 2017</td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 20.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of restricted stock that vested in the three months ended March 31, 2017 and 2016 was $46 and $47, respectively.</p>

<p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>8. LOAN AGREEMENT</b></p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b></p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On January 6, 2017, Oxford Finance LLC, as collateral agent and a lender (the “Lender”), and any additional lenders that may become parties thereto, entered into a loan and security agreement with us (the “Loan Agreement”).</p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><div style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Pursuant to the terms of the Loan Agreement, the Lender issued us a loan in the principal amount of  $15.0 million. The loan will bear interest at the rate equal to (a) the greater of  (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. The applicable interest rate on the loan at March 31, 2017 was 7.83%. We will have interest-only payments for 18 months, followed by an amortization period of 36 months. The maturity date of the loan is July 1, 2021. </div><p style="widows: 2; text-transform: none; background-color: white; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; background-color: white; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The expected remaining repayment of the $15 million loan principal is as follows:</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 1066px;">2018</td><td style="width: 13px;"> </td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 150px;">1,667</td><td style="text-align: left; width: 12px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">2019</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">5,000</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">2020</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">5,000</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">2021</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">3,333</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,000</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Upon the earlier of prepayment or the maturity date, we will pay to the Lender a final payment of 6% of the full principal amount of the loan. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b></p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">We paid the Lender an upfront facility fee of  $75,000.</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Pursuant to the terms of the Loan Agreement, we are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent, including, without limitation, incurring certain additional indebtedness, entering into certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. We are in compliance with the loan covenants at March 31, 2017.</p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by us thereunder will begin to bear interest at a rate that is 5% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lender. Events of default under the Loan Agreement include, among other things, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in our business, operations or financial condition ; the rendering of certain types of fines or judgments against us; any breach by us of any covenant (subject to cure for certain covenants only) made in the Loan Agreement; and the failure of any representation or warranty made by us in connection with the Loan Agreement to be correct in all material respects when made.</p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">We have granted Lender, a security interest in substantially all of our personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to the Lender under the Loan Agreement. We have also agreed not to encumber any of our intellectual property without required lenders’ prior written consent.</p><p style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><div style="widows: 2; text-transform: none; text-indent: 20pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with entering into the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of 354,330 shares of our common stock (the “Lender Warrants”). The warrants are exercisable immediately, have a per-share exercise price of  $1.27 and have a term of ten years. We have recorded the relative fair value of the warrants as a discount to the carrying value of the notes payable with a corresponding increase to additional paid in capital.</div>

<div><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>10. INCOME TAXES</b></p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">As of December 31, 2016, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $382,781, $202,137 and $27,779 respectively, which expire at various dates through 2036. Approximately $15,080 of our federal NOL and $929 of our state NOL were generated from excess tax deductions from share-based awards.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company adopted ASU No. 2016-09 in the first quarter of 2017. The recognition of the excess tax benefits from share-base payments mentioned above increased deferred tax assets and retained earnings accordingly. As the company doesn’t expect taxable income in the foreseeable future, we reserved the full amount at the time of the recognition and there was no impact on the net positions of deferred tax assets and retained earnings. The amount of excess tax benefits or deficiencies will fluctuate from period to period based on the price of our stock, the volume of share-based instruments settled or vested, and the value assigned to employee equity awards under U.S. GAAP and these fluctuations did not affect our net deferred tax position in the first quarter of 2017.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">At March 31, 2017 and December 31, 2016, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of March 31, 2017 and December 31, 2016, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2013 through 2016 and our state tax returns for the tax years 2013 through 2016 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><div style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2017, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.</div></div>

<div><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">March 31, 2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; font-style: italic;">Security type</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt; width: 603px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">9,305</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">—</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">(2</td><td style="text-align: left; padding-bottom: 2px; width: 15px;">)</td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">9,303</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">9,305</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(2</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">9,303</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">December 31, 2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="font-style: italic;" nowrap="nowrap">Security type</td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2" nowrap="nowrap"> </td><td> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt; width: 603px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">15,857</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">7</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">(5</td><td style="text-align: left; padding-bottom: 2px; width: 15px;">)</td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">15,859</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,857</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">7</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(5</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table></div>

<div><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>March 31,</b></p><p style="text-align: center; margin: 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2017</b></p></td><td style="padding-bottom: 2px;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 627px;">Cash equivalents</td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">2,947</td><td style="text-align: left; width: 16px;"> </td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">2,947</td><td style="text-align: left; width: 16px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">9,303</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">9,303</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">12,250</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">2,947</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">9,303</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 627px;">Cash equivalents</td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">12,923</td><td style="text-align: left; width: 16px;"> </td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">12,923</td><td style="text-align: left; width: 16px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">28,782</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">12,923</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table></div>

<div><table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">March 31,<br />2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 878px;">Accounts payable</td><td style="width: 13px;"> </td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 151px;">610</td><td style="text-align: left; width: 12px;"> </td><td style="width: 12px;"> </td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 150px;">710</td><td style="text-align: left; width: 12px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued payroll</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">772</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">1,856</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued outsourced pre-clinical and clinical fees</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">4,682</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">5,461</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued professional fees</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">663</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">363</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Other accrued expenses</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">437</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">310</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">7,164</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">8,700</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table></div>

<div><table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended<br />March 31,</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt; width: 866px;">Research and development</td><td style="width: 13px;"> </td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 151px;">130</td><td style="text-align: left; width: 12px;"> </td><td style="width: 12px;"> </td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 150px;">190</td><td style="text-align: left; width: 12px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 8.65pt;">General and administrative</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">413</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">404</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px; text-indent: -8.65pt; padding-left: 17.3pt;">Total stock-based compensation expense</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">543</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">594</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table></div>

<div><table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: left; font-weight: bold;"><b>Stock Options</b></td><td style="text-align: center;" nowrap="nowrap"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2"><b>Number of</b><br /><b>Shares</b></td><td style="text-align: center;" nowrap="nowrap"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2"><b>Weighted</b><br /><b>Average</b><br /><b>Exercise Price</b></td><td style="text-align: center;" nowrap="nowrap"> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt; width: 961px;">Outstanding as of December 31, 2016</td><td style="width: 29px;"> </td><td style="width: 14px;" nowrap="nowrap"> </td><td style="text-align: right; width: 169px;">8,715,048</td><td style="width: 28px;"> </td><td style="width: 14px;">$</td><td style="text-align: right; width: 169px;">3.71</td><td style="width: 14px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Granted</td><td> </td><td> </td><td style="text-align: right;">982,500</td><td> </td><td> </td><td style="text-align: right;">1.53</td><td> </td></tr><tr><td style="text-indent: -8.65pt; padding-left: 8.65pt; vertical-align: bottom;">Exercised</td><td style="vertical-align: bottom;"> </td><td style="vertical-align: bottom;"> </td><td style="text-align: right; vertical-align: top;">—</td><td style="vertical-align: top;"> </td><td style="vertical-align: bottom;"> </td><td style="text-align: right; vertical-align: bottom;">—</td><td style="vertical-align: bottom;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Cancelled</td><td> </td><td style="border-bottom: black 2px solid; text-align: right;"> </td><td style="border-bottom: black 2px solid; text-align: right;">(193,458</td><td>)</td><td style="border-bottom: black 2px solid; text-align: right;"> </td><td style="border-bottom: black 2px solid; text-align: right;">5.98</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Outstanding as of March 31, 2017</td><td> </td><td style="border-bottom: black 4px double; text-align: right;"> </td><td style="border-bottom: black 4px double; text-align: right;">9,504,090</td><td> </td><td style="border-bottom: black 4px double; text-align: left; vertical-align: bottom;">$</td><td style="border-bottom: black 4px double; text-align: right;">3.44</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;"> </td><td> </td><td style="border-bottom: black 2px solid; text-align: right;"> </td><td style="border-bottom: black 2px solid; text-align: right;"> </td><td> </td><td style="border-bottom: black 2px solid; text-align: right;"> </td><td style="border-bottom: black 2px solid; text-align: right;"> </td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable as of March 31, 2017</td><td> </td><td style="border-bottom: black 4px double; text-align: right;"> </td><td style="border-bottom: black 4px double; text-align: right;">6,481,588</td><td> </td><td style="border-bottom: black 4px double; text-align: left; vertical-align: bottom;">$</td><td style="border-bottom: black 4px double; text-align: right;">4.28</td><td> </td></tr></table></div>

<div><table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">Restricted Stock</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Number of Shares</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted Average<br />Grant Date<br />Fair Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="width: 878px;">Unvested as of December 31, 2016</td><td style="width: 13px;"> </td><td style="text-align: left; width: 13px;"> </td><td style="text-align: right; width: 151px;">29,276</td><td style="text-align: left; width: 12px;"> </td><td style="width: 12px;"> </td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 150px;">2.51</td><td style="text-align: left; width: 12px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt;">Vested</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">(29,276</td><td style="text-align: left; padding-bottom: 2px;">)</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">2.51</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px;">Unvested as of March 31, 2017</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;"> </td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table></div>

1667000

5000000

3333000

15000000

30 day U.S. LIBOR

0.0065

0.0685

0.0783

0.06 We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.

75000000

0.05

354330

1.27

P10Y 107700000 67700000

15857000

9305000

7000

5000

2000

15859000

9303000

12923000

2947000

28782000

12923000

15859000

12250000

2947000

9303000

710000

610000

1856000

772000

5461000 4682000

363000

663000

310000

437000

9477198

9504090

354330

3567956

594000

22000

190000

404000

543000

8000

130000

413000

8715048

9504090

982500

193458

6481588

3.71

3.44

1.53

5.98

4.28

9326234

3.44

P5Y10M24D

6481588

4.28

P4Y6M0D

29276

2.51

1.12

0.93

3000000

P3Y1M6D

182877

10581

P4Y6M0D

242697

P4Y

2.51

82617

160080

47000

46000

8027900

3567956

15200000

2.50

382781

202137

27779

15080

929

<div>more than 50 percentage points</div> P3Y P36M

P18M

EX-101.SCH 6 arql-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED BALANCE SHEETS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - COLLABORATIONS AND ALLIANCES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - STOCK OFFERING link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - LOAN AGREEMENT link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - LOAN AGREEMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - NET LOSS PER SHARE (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - STOCK OFFERING (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - LOAN AGREEMENT (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - LOAN AGREEMENT (Details Textuals) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - INCOME TAXES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 arql-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 arql-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 arql-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Marketable Securities, Current Marketable securities-short term Marketable securities-short term Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Net property and equipment Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent Other assets Total other assets Assets Total assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts payable and accrued expenses, Total Liabilities, Current Total current liabilities Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Notes Payable, Noncurrent Notes payable Liabilities Total liabilities Total liabilities Commitments and Contingencies Commitment and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding Common Stock, Value, Issued Common stock, $0.01 par value; 100,000,000 shares authorized; 71,146,597 and 71,146,209 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Additional Paid In Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Accumulated Other Comprehensive Income (Loss), Net Of Tax Accumulated other comprehensive income (loss) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Accumulated deficit Stockholders' Equity Attributable To Parent Balance Total stockholders' equity Balance Balance Liabilities and Equity Total liabilities and stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Income Statement [Abstract] Income Statement [Abstract] Revenues [Abstract] Revenue: Research and Development Revenue Net revenues Research and development revenue Aggregate revenue during the period from research and development agreements. Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development Research and development General and Administrative Expense General and administrative General and administrative Costs and Expenses Total costs and expenses Total costs and expenses Operating Income (Loss) Loss from operations Loss from operations Investment Income, Interest Interest income Interest Expense Interest expense Interest expense Net Income (Loss) Attributable To Parent Net income (loss) Net loss Net loss Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain (loss) on marketable securities Comprehensive Income (Loss), Net Of Tax, Attributable To Parent Comprehensive loss Comprehensive loss Earnings Per Share, Basic and Diluted [Abstract] Basic and diluted net loss per share: Earnings Per Share, Basic and Diluted Net earnings (loss) per share Net loss per share (in dollars per share) Net loss per share Net loss per share Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average basic and diluted common shares outstanding (in shares) Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization expense Depreciation and amortization Depreciation and amortization Accretion (Amortization) Of Discounts and Premiums, Investments Amortization of premium/discount on marketable securities Amortization of premium (discount) on marketable securities Amortization of Debt Discount (Premium) Amortization of debt discount Amortization of debt discount Share-Based Compensation Share-based compensation expense related to restricted stock Non-cash stock compensation Non-cash stock compensation Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) In Prepaid Expense and Other Assets Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid expenses and other assets Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Accounts payable and accrued expenses Increase (Decrease) In Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net use of cash Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments To Acquire Marketable Securities Purchases of marketable securities Purchases of marketable securities Purchases of marketable securities Proceeds From Sale and Maturity Of Marketable Securities Proceeds from sale or maturity of marketable securities Proceeds from sale or maturity of marketable securities Net Cash Provided By (Used In) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Notes Payable Proceeds from notes payable and warrants, net Proceeds from Issuance Initial Public Offering Proceeds from stock offering, net Proceeds from Stock Options Exercised Additional proceeds if options exercised Proceeds from stock option exercises and employee stock plan purchases Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash flows from financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Net increase in cash and cash equivalents Organization and Nature Of Operations [Abstract] Organization and Nature Of Operations [Abstract] Business Description and Basis of Presentation [Text Block] NATURE OF OPERATIONS AND BASIS OF PRESENTATION Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement Disclosure [Text Block] COLLABORATIONS AND ALLIANCES Marketable Securities and Fair Value Measurements [Abstract] Marketable Securities and Fair Value Measurements [Abstract] Financial Instruments Disclosure [Text Block] MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable and accrued expenses Earnings Per Share [Abstract] Loss per share: Earnings Per Share [Text Block] NET LOSS PER SHARE Compensation and Retirement Disclosure [Abstract] Compensation and Retirement Disclosure [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK-BASED COMPENSATION AND STOCK PLANS Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] STOCK OFFERING Long-term Debt, Unclassified [Abstract] Long-term Debt [Text Block] LOAN AGREEMENT New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] RECENT ACCOUNTING PRONOUNCEMENTS Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES Available-For-Sale Securities [Table Text Block] Schedule of fair value of available-for-sale marketable securities Fair Value, Assets Measured On Recurring Basis [Table Text Block] Schedule of assets measured at fair value on a recurring basis Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expense Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of stock-based compensation expense Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of activity of options under stock plans Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable [Table Text Block] Schedule of shares vested, expected to vest and exercisable Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of restricted stock activity Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of remaining loan repayment Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Loan agreement face amount Loan principal amount Schedule Of Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Type Of Arrangement and Non-Arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-Arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Daiichi Sankyo Tivantinib Agreement [Member] Daiichi Sankyo Tivantinib Agreement Contractual agreement of the company. Kyowa Hakko Kirin Licensing Agreement [Member] Kyowa Hakko Kirin Licensing Agreement Contractual agreement of the company. Products and Services [Axis] Products and Services [Domain] Phase 3 Collaboration Costs [Member] Phase 3 collaboration costs Represents information about Phase 3 collaboration costs. Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Cumulative Phase Costs Attributable To Collaboration Agreements Cumulative share of phase 3 collaboration costs The amount of cumulative share of costs since inception. Cumulative Phase Costs Attributable To Collaboration Agreements In Excess Of Milestone Payments and Royalties Cumulative share of phase 3 collaboration costs in excess of milestones amounts received The amount received in excess. Schedule Of Available-For-Sale Securities [Table] Schedule of Available-for-sale Securities [Table] Debt Security [Axis] Debt Security [Axis] Major Types Of Debt Securities [Domain] Major Types of Debt Securities [Domain] Corporate Debt Securities [Member] Corporate debt securities Corporate debt securities-short term & long term Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Current [Member] Short term Financial instruments current member. Schedule Of Available-For-Sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Available-For-Sale Securities, Amortized Cost Basis Amortized Cost Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Gross Unrealized Losses Available-for-sale Securities Fair Value Corporate debt securities-short term Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 Major Types Of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types Of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total Accounts Payable, Current Accounts payable Accrued Payroll Taxes, Current Accrued payroll Accrued Outsourced Preclinical and Clinical Fees Current Accrued outsourced pre-clinical and clinical fees Carrying value as of the balance sheet date of obligations incurred and payable for accrued outsourced pre clinical and clinical fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Professional Fees, Current Accrued professional fees Other Accrued Liabilities, Current Other accrued expenses Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Potential common shares issued upon exercise of outstanding stock options Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Share issued upon the exercise of outstanding employee stock warrant Incremental Common Shares Attributable To Call Option Share issued upon the exercise of outstanding employee stock options Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options using the treasury stock method. Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Research and Development Expense [Member] Research and development General and Administrative Expense [Member] General and administrative Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Allocated Share-Based Compensation Expense Total stock-based compensation expense Share-based compensation expense Stock-based compensation expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Award Type [Domain] Employee Stock Option [Member] Stock Options Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Number of Options Outstanding at December 31, 2013 Outstanding as of December 31, 2011 Outstanding as of December 31, 2016 Outstanding as of March 31, 2017 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Employment agreement to grant CEO stock option Granted Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Number of the non-vested options shares , Forfeited during the period Cancelled Cancelled Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Options Exercisable as of December 31, 2013 Exercisable as of March 31, 2017 Number of shares currently exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Outstanding, Weighted Average Exercise Price Outstanding as of December 31, 2011 Outstanding as of December 31, 2016 Outstanding as of March 31, 2017 Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise price of the options non vested which are forfeited during the period Cancelled Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options Exercisable, Weighted Average Exercise Price Exercisable as of March 31, 2017 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Vested and unvested expected to vest shares Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Exercise Price Vested and unvested expected to vest, weighted-average exercise price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and unvested expected to vest, weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Aggregate Intrinsic Value Vested and unvested expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable, Number Exercisable shares EX-101.PRE 10 arql-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	Apr. 20, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ARQULE INC
Entity Central Index Key	0001019695
Trading Symbol	arql
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		71,146,597
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 28,237	$ 15,267
Marketable securities-short term	9,303	15,859
Prepaid expenses and other current assets	630	822
Total current assets	38,170	31,948
Property and equipment, net	156	180
Other assets	164	252
Total assets	38,490	32,380
Current liabilities:
Accounts payable and accrued expenses	7,164	8,700
Total current liabilities	7,164	8,700
Long-term liabilities:
Notes payable	14,337
Total liabilities	21,501	8,700
Commitment and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized; 71,146,597 and 71,146,209 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	711	711
Additional paid-in capital	528,691	527,802
Accumulated other comprehensive income (loss)	(2)	2
Accumulated deficit	(512,411)	(504,835)
Total stockholders' equity	16,989	23,680
Total liabilities and stockholders' equity	$ 38,490	$ 32,380

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	71,146,597	71,146,209
Common stock, shares outstanding	71,146,597	71,146,209

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Research and development revenue		$ 1,227
Costs and expenses:
Research and development	$ 5,194	4,198
General and administrative	2,074	2,044
Total costs and expenses	7,268	6,242
Loss from operations	(7,268)	(5,015)
Interest income	22	34
Interest expense	(330)
Net loss	(7,576)	(4,981)
Unrealized gain (loss) on marketable securities	(4)	29
Comprehensive loss	$ (7,580)	$ (4,952)
Basic and diluted net loss per share:
Net loss per share (in dollars per share)	$ (0.11)	$ (0.08)
Weighted average basic and diluted common shares outstanding (in shares)	71,138	65,489

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (7,576)	$ (4,981)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24	27
Amortization of premium (discount) on marketable securities	(3)	26
Amortization of debt discount	60
Non-cash stock compensation	543	594
Changes in operating assets and liabilities:
Prepaid expenses and other assets	280	(115)
Accounts payable and accrued expenses	(1,653)	(843)
Deferred revenue		(1,140)
Net cash used in operating activities	(8,325)	(6,432)
Cash flows from investing activities:
Purchases of marketable securities	(1)	(13,386)
Proceeds from sale or maturity of marketable securities	6,556	10,498
Net cash provided by (used in) investing activities	6,555	(2,888)
Cash flows from financing activities:
Proceeds from notes payable and warrants, net	14,740
Proceeds from stock offering, net		15,185
Proceeds from stock option exercises and employee stock plan purchases		114
Net cash provided by financing activities	14,740	15,299
Net increase in cash and cash equivalents	12,970	5,979
Cash and cash equivalents, beginning of period	15,267	13,983
Cash and cash equivalents, end of period	$ 28,237	$ 19,962

XML 16 R6.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2017

Organization and Nature Of Operations [Abstract]

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

•

ARQ 751, a next-generation inhibitor of AKT, in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation;

•

ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, planned to advance to Phase 1 by Q3 2017; and

•

XML 17 R7.htm IDEA: XBRL DOCUMENT

COLLABORATIONS AND ALLIANCES

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

COLLABORATIONS AND ALLIANCES

2. COLLABORATIONS AND ALLIANCES

Daiichi Sankyo Tivantinib Agreement

For the quarters ended March 31, 2017 and 2016, zero and $0.7 million, respectively, were recognized as net revenue.

Kyowa Hakko Kirin Licensing Agreement

For the quarters ended March 31, 2017 and 2016, zero and $0.5 million, respectively, were recognized as revenue.

XML 18 R8.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2017

Marketable Securities and Fair Value Measurements [Abstract]

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

The following is a summary of the fair value of available-for-sale marketable securities we held at March 31, 2017 and

December 31, 2016:

March 31, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	9,305	$	—	$	(2	)	$	9,303
Total available-for-sale marketable securities	$	9,305	$	—	$	(2	)	$	9,303

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	15,857	$	7	$	(5	)	$	15,859
Total available-for-sale marketable securities	$	15,857	$	7	$	(5	)	$	15,859

Our available-for-sale marketable securities in a loss position at March 31, 2017, and December 31, 2016 were in a continuous unrealized loss position for less than 12 months.

	March 31, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	2,947	$	2,947	$	—	$	—
Corporate debt securities-short term		9,303		—		9,303		—
Total	$	12,250	$	2,947	$	9,303	$	—

	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	12,923	$	12,923	$	—	$	—
Corporate debt securities-short term		15,859		—		15,859		—
Total	$	28,782	$	12,923	$	15,859	$	—

XML 19 R9.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Accounts payable and accrued expenses

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at March 31, 2017 and December 31, 2016:

	March 31, 2017		December 31, 2016
Accounts payable	$	610	$	710
Accrued payroll		772		1,856
Accrued outsourced pre-clinical and clinical fees		4,682		5,461
Accrued professional fees		663		363
Other accrued expenses		437		310
	$	7,164	$	8,700

XML 20 R10.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE	3 Months Ended
NET LOSS PER SHARE	Mar. 31, 2017
Earnings Per Share [Abstract]
NET LOSS PER SHARE	5. NET LOSS PER SHARE Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three months ended March 31, 2017, include 9,504,090 shares that would be issued upon the exercise of outstanding employee stock options and 354,330 shares that would be issued upon the exercise of the warrants issued in conjunction with our January 6, 2017 loan agreement. Potential common shares, for the three months ended March 31, 2016, include 9,477,198 shares that would be issued upon the exercise of outstanding employee stock options, and 3,567,956 shares that would have been issued upon exercise of stock options issued in our February 26, 2016 stock offering.

XML 21 R11.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS

3 Months Ended

Mar. 31, 2017

Compensation and Retirement Disclosure [Abstract]

STOCK-BASED COMPENSATION AND STOCK PLANS

6. STOCK-BASED COMPENSATION AND STOCK PLANS

The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:

	Three Months Ended March 31,
	2017		2016
Research and development	$	130	$	190
General and administrative		413		404
Total stock-based compensation expense	$	543	$	594

In the three months ended March 31, 2017 and 2016, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.

Option activity under our stock plans for the three months ended March 31, 2017 was as follows:

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016		8,715,048		$	3.71
Granted		982,500			1.53
Exercised		—			—
Cancelled		(193,458	)		5.98
Outstanding as of March 31, 2017		9,504,090		$	3.44

Exercisable as of March 31, 2017		6,481,588		$	4.28

Shares vested, expected to vest and exercisable at March 31, 2017 are as follows:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at March 31, 2017		9,326,234	$	3.44		5.9	$	—
Exercisable at March 31, 2017		6,481,588	$	4.28		4.5	$	—

Restricted stock activity under the Plan for the three months ended March 31, 2017 was as follows:

Restricted Stock	Number of Shares			Weighted Average Grant Date Fair Value
Unvested as of December 31, 2016		29,276		$	2.51
Vested		(29,276	)		2.51
Unvested as of March 31, 2017		—		$	—

The fair value of restricted stock that vested in the three months ended March 31, 2017 and 2016 was $46 and $47, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

STOCK OFFERING	3 Months Ended
STOCK OFFERING	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
STOCK OFFERING	7. STOCK OFFERING On February 26, 2016, we entered into definitive stock purchase agreements with certain institutional and accredited investors. In conjunction with this stock offering we issued 8,027,900 shares of our common stock and non-transferable options for 3,567,956 shares of our common stock for aggregate net proceeds of $15.2 million. Each option was exercisable for $2.50 per share and they all expired on March 22, 2017.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT

3 Months Ended

Mar. 31, 2017

Long-term Debt, Unclassified [Abstract]

LOAN AGREEMENT

8. LOAN AGREEMENT

The expected remaining repayment of the $15 million loan principal is as follows:

2018	$	1,667
2019		5,000
2020		5,000
2021		3,333
	$	15,000

We paid the Lender an upfront facility fee of $75,000.

XML 24 R14.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

3 Months Ended

Mar. 31, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

9. RECENT ACCOUNTING PRONOUNCEMENTS

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 31, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES As of December 31, 2016, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $382,781, $202,137 and $27,779 respectively, which expire at various dates through 2036. Approximately $15,080 of our federal NOL and $929 of our state NOL were generated from excess tax deductions from share-based awards. The Company adopted ASU No. 2016-09 in the first quarter of 2017. The recognition of the excess tax benefits from share-base payments mentioned above increased deferred tax assets and retained earnings accordingly. As the company doesn’t expect taxable income in the foreseeable future, we reserved the full amount at the time of the recognition and there was no impact on the net positions of deferred tax assets and retained earnings. The amount of excess tax benefits or deficiencies will fluctuate from period to period based on the price of our stock, the volume of share-based instruments settled or vested, and the value assigned to employee equity awards under U.S. GAAP and these fluctuations did not affect our net deferred tax position in the first quarter of 2017. At March 31, 2017 and December 31, 2016, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of March 31, 2017 and December 31, 2016, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2013 through 2016 and our state tax returns for the tax years 2013 through 2016 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards. Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2017, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.

XML 26 R16.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2017

Marketable Securities and Fair Value Measurements [Abstract]

Schedule of fair value of available-for-sale marketable securities

March 31, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	9,305	$	—	$	(2	)	$	9,303
Total available-for-sale marketable securities	$	9,305	$	—	$	(2	)	$	9,303

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	15,857	$	7	$	(5	)	$	15,859
Total available-for-sale marketable securities	$	15,857	$	7	$	(5	)	$	15,859

Schedule of assets measured at fair value on a recurring basis

	March 31, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	2,947	$	2,947	$	—	$	—
Corporate debt securities-short term		9,303		—		9,303		—
Total	$	12,250	$	2,947	$	9,303	$	—

	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	12,923	$	12,923	$	—	$	—
Corporate debt securities-short term		15,859		—		15,859		—
Total	$	28,782	$	12,923	$	15,859	$	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued expense

	March 31, 2017		December 31, 2016
Accounts payable	$	610	$	710
Accrued payroll		772		1,856
Accrued outsourced pre-clinical and clinical fees		4,682		5,461
Accrued professional fees		663		363
Other accrued expenses		437		310
	$	7,164	$	8,700

XML 28 R18.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Tables)

3 Months Ended

Mar. 31, 2017

Compensation and Retirement Disclosure [Abstract]

Schedule of stock-based compensation expense

	Three Months Ended March 31,
	2017		2016
Research and development	$	130	$	190
General and administrative		413		404
Total stock-based compensation expense	$	543	$	594

Schedule of activity of options under stock plans

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016		8,715,048		$	3.71
Granted		982,500			1.53
Exercised		—			—
Cancelled		(193,458	)		5.98
Outstanding as of March 31, 2017		9,504,090		$	3.44

Exercisable as of March 31, 2017		6,481,588		$	4.28

Schedule of shares vested, expected to vest and exercisable

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at March 31, 2017		9,326,234	$	3.44		5.9	$	—
Exercisable at March 31, 2017		6,481,588	$	4.28		4.5	$	—

Schedule of restricted stock activity

Restricted Stock	Number of Shares			Weighted Average Grant Date Fair Value
Unvested as of December 31, 2016		29,276		$	2.51
Vested		(29,276	)		2.51
Unvested as of March 31, 2017		—		$	—

XML 29 R19.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT (Tables)

3 Months Ended

Mar. 31, 2017

Long-term Debt, Unclassified [Abstract]

Schedule of remaining loan repayment

2018	$	1,667
2019		5,000
2020		5,000
2021		3,333
	$	15,000

XML 30 R20.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Jan. 06, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Net use of cash	$ (8,325)	$ (6,432)
Loan principal amount			$ 15,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

COLLABORATIONS AND ALLIANCES (Detail Textuals) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenues		$ 1,227,000
Daiichi Sankyo Tivantinib Agreement \| Phase 3 collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cumulative share of phase 3 collaboration costs	$ 107,700,000
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received	67,700,000
Net revenues	0	700,000
Kyowa Hakko Kirin Licensing Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenues	$ 0	$ 500,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 9,305	$ 15,857
Gross Unrealized Gains		7
Gross Unrealized Losses	(2)	(5)
Fair Value	9,303	15,859
Corporate debt securities \| Short term
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	9,305	15,857
Gross Unrealized Gains		7
Gross Unrealized Losses	(2)	(5)
Fair Value	$ 9,303	$ 15,859

XML 33 R23.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term	$ 9,303	$ 15,859
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,947	12,923
Total	12,250	28,782
Fair Value, Measurements, Recurring \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term	9,303	15,859
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,947	12,923
Total	2,947	12,923
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets (Level 1) \| Corporate debt securities \| Short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total	9,303	15,859
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Corporate debt securities \| Short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term	9,303	15,859
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| Corporate debt securities \| Short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term

XML 34 R24.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 610	$ 710
Accrued payroll	772	1,856
Accrued outsourced pre-clinical and clinical fees	4,682	5,461
Accrued professional fees	663	363
Other accrued expenses	437	310
Accounts payable and accrued expenses, Total	$ 7,164	$ 8,700

XML 35 R25.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Detail Textuals) - shares	3 Months Ended
NET LOSS PER SHARE (Detail Textuals) - shares	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Potential common shares issued upon exercise of outstanding stock options	9,504,090	9,477,198
Share issued upon the exercise of outstanding employee stock warrant	354,330
Share issued upon the exercise of outstanding employee stock options		3,567,956

XML 36 R26.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 543	$ 594
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	130	190
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 413	$ 404

XML 37 R27.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) - Stock Options	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Number of Shares
Outstanding as of December 31, 2016 \| shares	8,715,048
Granted \| shares	982,500
Exercised \| shares
Cancelled \| shares	(193,458)
Outstanding as of March 31, 2017 \| shares	9,504,090
Exercisable as of March 31, 2017 \| shares	6,481,588
Weighted Average Exercise Price
Outstanding as of December 31, 2016 \| $ / shares	$ 3.71
Granted \| $ / shares	1.53
Exercised \| $ / shares
Cancelled \| $ / shares	5.98
Outstanding as of March 31, 2017 \| $ / shares	3.44
Exercisable as of March 31, 2017 \| $ / shares	$ 4.28

XML 38 R28.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) - Stock Options	3 Months Ended
	Mar. 31, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and unvested expected to vest shares \| shares	9,326,234
Vested and unvested expected to vest, weighted-average exercise price \| $ / shares	$ 3.44
Vested and unvested expected to vest, weighted-average remaining contractual term (in years)	5 years 10 months 24 days
Vested and unvested expected to vest, aggregate intrinsic value \| $
Exercisable shares \| shares	6,481,588
Exercisable, weighted-average exercise price \| $ / shares	$ 4.28
Exercisable, weighted-average remaining contractual term (in years)	4 years 6 months
Exercisable, aggregate intrinsic value \| $

XML 39 R29.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) - Restricted Stock	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Number of Shares
Unvested as of December 31, 2016 \| shares	29,276
Vested \| shares	(29,276)
Unvested as of March 31, 2017 \| shares
Weighted Average Grant Date Fair Value
Unvested as of December 31, 2016 \| $ / shares	$ 2.51
Vested \| $ / shares	2.51
Unvested as of March 31, 2017 \| $ / shares

XML 40 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) - Stock Options - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted (in dollars per share)	$ 0.93	$ 1.12
Intrinsic value of options exercised	$ 0
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options	$ 3,000,000
Compensation cost related to non-vested option awards recognition period	3 years 1 month 6 days
Number of the non-vested options shares expired during the period	182,877
Number of options forfeited during the period	10,581
Weighted average remaining contractual life for options exercisable	4 years 6 months

XML 41 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 543	$ 594
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted			242,697
Award vesting period			4 years
Weighted average grant date fair value for the options granted during the period (in dollars per share)			$ 2.51
Number of shares forfeited	82,617
Number of shares vested during the period	160,080
Share-based compensation expense	$ 8	22
Fair value of stock vested during period	$ 46	$ 47

XML 42 R32.htm IDEA: XBRL DOCUMENT

STOCK OFFERING (Detail Textuals) - Definitive stock purchase agreements $ / shares in Units, $ in Millions	1 Months Ended
	Feb. 26, 2016 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued under agreement	8,027,900
Number of non transferable options issued	3,567,956
Aggregate net proceeds \| $	$ 15.2
Stock option exercise price (in dollars per share) \| $ / shares	$ 2.50

XML 43 R33.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT (Details) $ in Thousands	Jan. 06, 2017 USD ($)
Long-term Debt, Unclassified [Abstract]
2018	$ 1,667
2019	5,000
2020	5,000
2021	3,333
Long-term Debt, Fair Value	$ 15,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT (Details Textuals) - USD ($) $ / shares in Units, $ in Thousands	Jan. 06, 2017	Mar. 31, 2017
Long-term Debt, Unclassified [Abstract]
Loan agreement face amount	$ 15,000
Debt Instrument description	30 day U.S. LIBOR
Percentage of interest rate basis	0.65%
Percentage of interest rate during the period	6.85%
Percentage of interest rate end of the period		7.83%
Interest only-payment duration	18 months
Debt amortization period	36 months
Expected remaining repayment	$ 15,000
Percentage of principal amount of loan for final payment	6.00%
Prepayment amount description	We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.
Lender upfront facility fee	$ 75,000
Percentage debt instrument default interest rate	5.00%
Number of warrants issued to purchase common stock	354,330
Exercise price of warrants or rights	$ 1.27
Term of warrant	10 years

XML 45 R35.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Detail Textuals) - USD ($)	3 Months Ended	12 Months Ended
INCOME TAXES (Detail Textuals) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Increase in ownership percentage of certain stockholders or public groups	more than 50 percentage points
Ownership change, increase in ownership percentage, term	3 years
Federal income tax
Operating Loss Carryforwards [Line Items]
Net operating loss		$ 382,781
Net operating loss generated from excess tax deduction from share based awards		15,080
State income tax
Operating Loss Carryforwards [Line Items]
Net operating loss		202,137
Net operating loss generated from excess tax deduction from share based awards		929
Research and development credit carryforwards
Operating Loss Carryforwards [Line Items]
Net operating loss		$ 27,779

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 50 163 1 false 18 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.arqule.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED BALANCE SHEETS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDBALANCESHEETSUnaudited CONDENSED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) Sheet http://www.arqule.com/role/CONDENSEDBALANCESHEETSUnauditedParentheticals CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 6 false false R7.htm 007 - Disclosure - COLLABORATIONS AND ALLIANCES Sheet http://www.arqule.com/role/COLLABORATIONSANDALLIANCES COLLABORATIONS AND ALLIANCES Notes 7 false false R8.htm 008 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Notes 8 false false R9.htm 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 9 false false R10.htm 010 - Disclosure - NET LOSS PER SHARE Sheet http://www.arqule.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 10 false false R11.htm 011 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANS STOCK-BASED COMPENSATION AND STOCK PLANS Notes 11 false false R12.htm 012 - Disclosure - STOCK OFFERING Sheet http://www.arqule.com/role/StockOffering STOCK OFFERING Notes 12 false false R13.htm 013 - Disclosure - LOAN AGREEMENT Sheet http://www.arqule.com/role/LoanAgreement LOAN AGREEMENT Notes 13 false false R14.htm 014 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.arqule.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 14 false false R15.htm 015 - Disclosure - INCOME TAXES Sheet http://www.arqule.com/role/INCOMETAXES INCOME TAXES Notes 15 false false R16.htm 016 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS 16 false false R17.htm 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES 17 false false R18.htm 018 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Tables http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANS 18 false false R19.htm 019 - Disclosure - LOAN AGREEMENT (Tables) Sheet http://www.arqule.com/role/LOANAGREEMENTTables LOAN AGREEMENT (Tables) Tables http://www.arqule.com/role/LoanAgreement 19 false false R20.htm 020 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) Sheet http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATIONDetailTextuals NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) Details http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION 20 false false R21.htm 021 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals) Sheet http://www.arqule.com/role/CollaborationsAndAlliancesDetailTextuals COLLABORATIONS AND ALLIANCES (Detail Textuals) Details http://www.arqule.com/role/COLLABORATIONSANDALLIANCES 21 false false R22.htm 022 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryOfFairValueOfAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Details 22 false false R23.htm 023 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) Sheet http://www.arqule.com/role/Marketablesecuritiesandfairvaluemeasurementsassetsmeasuredatfairvalueonrecurringbasisdetails1 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) Details 23 false false R24.htm 024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESSummaryOfAccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Details 24 false false R25.htm 025 - Disclosure - NET LOSS PER SHARE (Detail Textuals) Sheet http://www.arqule.com/role/NETLOSSPERSHAREDetailTextuals NET LOSS PER SHARE (Detail Textuals) Details http://www.arqule.com/role/NETLOSSPERSHARE 25 false false R26.htm 026 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Details 26 false false R27.htm 027 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSOptionActivityDetails1 STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) Details 27 false false R28.htm 028 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSSharesVestedExpectedToVestAndExercisableDetails2 STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) Details 28 false false R29.htm 029 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSRestrictedStockActivityDetails3 STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) Details 29 false false R30.htm 030 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSDetailTextuals STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 30 false false R31.htm 031 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSDetailTextuals1 STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 31 false false R32.htm 032 - Disclosure - STOCK OFFERING (Detail Textuals) Sheet http://www.arqule.com/role/STOCKOFFERINGDetailTextuals STOCK OFFERING (Detail Textuals) Details http://www.arqule.com/role/StockOffering 32 false false R33.htm 033 - Disclosure - LOAN AGREEMENT (Details) Sheet http://www.arqule.com/role/LOANAGREEMENTDetails LOAN AGREEMENT (Details) Details http://www.arqule.com/role/LOANAGREEMENTTables 33 false false R34.htm 034 - Disclosure - LOAN AGREEMENT (Details Textuals) Sheet http://www.arqule.com/role/LoanAgreementDetailsTextuals LOAN AGREEMENT (Details Textuals) Details http://www.arqule.com/role/LOANAGREEMENTTables 34 false false R35.htm 035 - Disclosure - INCOME TAXES (Detail Textuals) Sheet http://www.arqule.com/role/INCOMETAXESDetailTextuals INCOME TAXES (Detail Textuals) Details http://www.arqule.com/role/INCOMETAXES 35 false false All Reports Book All Reports arql-20170331.xml arql-20170331.xsd arql-20170331_cal.xml arql-20170331_def.xml arql-20170331_lab.xml arql-20170331_pre.xml true true ZIP 52 0001571049-17-004369-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-17-004369-xbrl.zip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
7%DC:]RW9Y]L M>SZ[#< &JPUZO>=6]S/ MQ/J=O) PIM^?WMH#^^N$**,@R?G=E-5:>TY&+M:RV2=K:@LJYUFCDC3,YD[_ M,]9MF\XH&!95)HR5_C#!DZD@MT0Z*DMK'+I_.*L51'C7)$C529.2[Q^%(+#N M$81D\19[_VF3DN^?VGTR]21J.1Q_G$R=,?[8EQF'.7V4I' XQL+'P_RKZ!@[ M;E#CG#4'=SX4W%H4Z+?J^4N&?-'.JI]'9*@6[Z[LF':LL?5Q:E/YR5"8U;"F M7
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end